Delivering higher rates of clinical remission, demonstrating more gut-selective pharmacology and minimizing adverse side effects of your IBD candidate Developed in combination with 20 stakeholders including AbbVie, Theravance and Genentech: GIIDS will be the first end-to-end drug development forum focused exclusively on delivering more clinically safe and efficacious treatments for patients suffering from chronic GI inflammation.
Across 3 days of in-depth discussion, share perspectives with industry leaders and overcome translational drug development challenges including: clinical trial design in a hyper-competitive landscape, targeting alternative proinflammatory pathways, and the potential of emerging antigen-specific and bio-therapeutics.
Be part of this inaugural summit to collaborate and gain the knowledge you need to confidently navigate the next 12 months of your anti-inflammatory and IBD research.
Conference + 1 Workshop: USD 3498.0
Conference Only: USD 2899.0
Workshop Only: USD 699.0